Propranolol for infantile haemangiomas: a review
نویسندگان
چکیده
منابع مشابه
Propranolol for infantile haemangiomas: a review.
Infantile haemangiomas are the most common benign tumour of infancy. However the majority are self-resolving and only a small minority of cases require treatment, with various different medications being used in the past. Over the last few years, propranolol, a non-selective β-blocker, has become a popular and successful treatment for infantile haemangiomas. However, further research on its saf...
متن کاملPropranolol therapy for infantile haemangiomas: review of the literature.
OBJECTIVES Haemangiomas are the most common tumors of infancy affecting approximately 1 in 10 children. Unlike other tumors, haemangiomas enter an involution phase, during which they usually regress over the next several months to years. Sometimes intervention is required due to proliferative growth which is complicated by ulceration, bleeding, persistent aesthetic deformity or infection. MET...
متن کاملInfantile Haemangiomas: A Review on Treatment Modalities
Background: Infantile haemangioma is the most common benign vascular tumor in children. They are more common in females and in infants born prematurely. Haemangiomas are mostly found on the head and neck regions (60 %), and are classified according to their depth. Most common complication is ulceration which affects nearly 15 25 % of patients. Diagnosis is mainly based on history and physical e...
متن کاملUse of propranolol in infantile haemangiomas: report of five cases and review of the literature.
Infantile haemangiomas are common benign tumours that do not require treatment unless they cause significant functional impairment or disfigurement. We report our experience with the off-label use of propranolol in 5 children with haemangiomas and review the relevant literature.
متن کاملpropranolol in infantile hemangioma: a review article
hemangioma is the most common benign cutaneous vascular tumor in infants and children. the hemangioma incidence in the neonates is 2% to 3% that increases to 10% in those younger than one year of age. before introduction of propranolol in 2008, different medications such as systemic corticosteroids and vincristine, with different side effects, were used for years. since then, over 200 studies c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Disease in Childhood
سال: 2011
ISSN: 0003-9888,1468-2044
DOI: 10.1136/adc.2010.208884